AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)-- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that the company will participate in the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

A pre-recorded fireside chat will be available from Monday, November 22 to Thursday, December 2, 2021, on the conference website and on the Investors & Press section of the AlloVir website at https://ir.allovir.com.

About AlloVir

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005508/en/

Sonia Choi

AlloVir

schoi@allovir.com

Source: AlloVir, Inc.